A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Advanced Endometrial Cancer Clinical Trial

Official title:
A Open-label, Multicenter Phase II Study of TQB2450 Injection or Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Status Recruiting

Clinical Trial Summary

This is a study to evaluate the efficacy and safety of TQB2450 injection or combined with anlotinib hydrochloride capsule in the treatment of recurrent or metastatic advanced endometrial cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04574284
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact	Xiaohua Wu, Doctor
Email	wu.xh@fudan.edu.cn
Status	Recruiting
Phase	Phase 2
Start date	September 29, 2020
Completion date	April 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT06046274` - GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer	Phase 2
Recruiting	`NCT05112991` - Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer	Phase 2
Not yet recruiting	`NCT05106127` - Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem	Phase 2
Completed	`NCT01289041` - BKM120 as Second-line Therapy for Advanced Endometrial Cancer	Phase 2
Not yet recruiting	`NCT05077215` - Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer	Phase 3
Recruiting	`NCT05481645` - Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.	Phase 2